Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
NIOX Group Plc (NIOX.L)
GBp59.20
+0.60 (+1.02%)
GB LSE Healthcare Medical - Devices
Address
Hayakawa Building OX4 4GB
Oxford, GB
Oxford, GB
CEO
Jonathan Charles Emms
Website
investors.niox.com
IPO
2014-03-13
ISIN GB00BJVD3B28
Also trades on
London Stock Exchange · CIR.L (GBp)
London Stock Exchange · NIOX.L (GBp)
Other OTC · CSSPF (USD)
Description
NIOX Group Plc is a worldwide company dedicated to innovating, developing, and distributing medical devices that measure fractional exhaled nitric oxide (FeNO). A key product is the NIOX VERO system, an easily portable and non-invasive diagnostic tool designed for immediate, on-site patient use. This system includes a compact device alongside a suite of disposable items like sensors, individual mouthpieces, and breathing handles, all essential for quantifying FeNO levels in patients. The company, which was founded in 2006 and is headquartered in Oxford, United Kingdom, was formerly known as Circassia Group Plc until its renaming to NIOX Group Plc in September 2022.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
GBp59.20
+0.60 (+1.02%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
880.5K
Beta
-0.09
Float Shares
329.25M
Free Float %
78.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.40% | -6.53% | -16.18% | -12.31% | -20.17% | -14.16% | -16.42% | -8.95% | +63.79% | -78.81% | -81.61% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
59.20
DCF (Unlevered)
112.95
+90.8%
DCF (Levered)
172.74
+191.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
19.93
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+16.5% ★ Q4'25: +30.6% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+97.6% ★ Q4'25: -82.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+12.1% Q4'25: +36.6% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+22.0% ★ Q4'25: +20.9% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+13.7% ★ Q4'25: +24.1% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%-4.9% ★ Q4'25: -5.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.09× ★ Q4'25: 0.05× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10.80M
est: 9.93M (+8.7%)
|
23.10M
est: 24.58M (-6.0%)
|
46.30M
est: 46.37M (-0.1%)
|
48.30M
est: 49.10M (-1.6%)
|
34.60M
est: 62.40M (-44.6%)
|
23.90M
est: 26.00M (-8.1%)
|
27.90M
est: 27.90M (+0.0%)
|
31.30M
est: 31.30M (+0.0%)
|
36.80M
est: 39.00M (-5.6%)
|
41.80M
est: 41.80M (+0.0%)
|
48.70M
est: 48.70M (+0.0%)
|
50.36M
49.17M – 51.38M
+3.4% YoY
|
54.45M
53.10M – 55.48M
+8.1% YoY
|
57.51M
57.22M – 57.79M
+5.6% YoY
|
| EBITDA |
-64.60M
est: 1.47M (-4,484.4%)
|
-33.50M
est: 3.64M (-1,019.1%)
|
-66.60M
est: 6.88M (-1,068.5%)
|
-39.50M
est: 7.28M (-642.4%)
|
-12.30M
est: 9.25M (-232.9%)
|
-9.10M
est: 3.86M (-336.0%)
|
3.10M
est: 4.14M (-25.1%)
|
15.20M
est: 4.64M (+227.4%)
|
8.60M
est: 10.47M (-17.8%)
|
12.20M
est: 11.22M (+8.7%)
|
10.70M
est: 13.07M (-18.1%)
|
13.52M
13.20M – 13.79M
+3.4% YoY
|
14.61M
14.25M – 14.89M
+8.1% YoY
|
15.43M
15.36M – 15.51M
+5.6% YoY
|
| EBIT |
-67.50M
est: -353.0K (-19,021.4%)
|
-38.70M
est: -873.2K (-4,331.9%)
|
-74.10M
est: -1.65M (-4,397.7%)
|
-43.90M
est: -1.74M (-2,416.3%)
|
-27.30M
est: -2.22M (-1,131.3%)
|
-18.10M
est: -923.8K (-1,859.2%)
|
-1.80M
est: -991.4K (-81.6%)
|
10.60M
est: -1.11M (+1,053.1%)
|
4.20M
est: 6.24M (-32.6%)
|
8.00M
est: 6.68M (+19.7%)
|
10.70M
est: 7.79M (+37.4%)
|
8.05M
7.86M – 8.21M
+3.4% YoY
|
8.70M
8.49M – 8.87M
+8.1% YoY
|
9.19M
9.15M – 9.24M
+5.6% YoY
|
| Net Income |
-49.90M
est: -106.37M (+53.1%)
|
-137.30M
est: -146.76M (+6.4%)
|
-99.10M
est: -108.02M (+8.3%)
|
-117.10M
est: -41.93M (-179.3%)
|
-48.30M
est: -42.13M (-14.6%)
|
-33.50M
est: -17.48M (-91.6%)
|
3.60M
est: 3.09M (+16.4%)
|
16.10M
est: 7.51M (+114.5%)
|
10.70M
est: 11.00M (-2.7%)
|
3.70M
est: 12.32M (-70.0%)
|
7.00M
est: 10.86M (-35.5%)
|
11.90M
11.46M – 17.11M
+9.6% YoY
|
13.66M
13.22M – 18.77M
+14.8% YoY
|
14.92M
14.50M – 15.35M
+9.2% YoY
|
| SGA |
27.20M
est: 6.66M (+308.4%)
|
41.60M
est: 16.48M (+152.5%)
|
59.90M
est: 31.09M (+92.7%)
|
65.80M
est: 32.92M (+99.9%)
|
38.20M
est: 41.84M (-8.7%)
|
26.80M
est: 17.43M (+53.7%)
|
18.70M
est: 18.71M (0.0%)
|
17.20M
est: 20.98M (-18.0%)
|
19.60M
est: 20.01M (-2.1%)
|
20.00M
est: 21.45M (-6.8%)
|
16.30M
est: 24.99M (-34.8%)
|
25.84M
25.23M – 26.36M
+3.4% YoY
|
27.94M
27.25M – 28.47M
+8.1% YoY
|
29.51M
29.36M – 29.65M
+5.6% YoY
|
| EPS |
-0.20
est: -0.24 (+15.7%)
|
-0.48
est: -0.33 (-46.6%)
|
-0.31
est: -0.24 (-28.6%)
|
-0.14
est: -0.09 (-49.7%)
|
-0.13
est: -0.09 (-38.3%)
|
-0.09
est: -0.04 (-124.9%)
|
0.01
est: 0.01 (+26.0%)
|
0.04
est: 0.02 (+129.3%)
|
0.03
est: 0.03 (-2.2%)
|
0.01
est: 0.03 (-69.7%)
|
0.02
est: 0.03 (-33.6%)
|
0.03
0.03 – 0.04
+24.8% YoY
|
0.04
0.03 – 0.04
+13.0% YoY
|
0.04
0.03 – 0.04
-2.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
34.14M
OE per share TTM
0.08
Owner's Yield
14.16%
Maintenance CapEx ratio
3.45%
Maint CapEx / Avg PPE
4.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 4 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Europe SmallCap Dividend UCITS ETF Acc DFEA.L | 0.05% | 45.3K | 0.38% |
| 2 | WisdomTree Europe SmallCap Dividend UCITS ETF WTES.DE | 0.05% | 45.3K | 0.38% |
| 3 | WisdomTree Dynamic International SmallCap Equity ETF DDLS | 0.03% | 143.0K | 0.48% |
| 4 | WisdomTree International SmallCap Dividend Fund DLS | 0.03% | 324.2K | 0.58% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
117.6K
Shares Outstanding
420.70M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jonathan Emms | Chief Executive Officer & Executive Director | 806.0K | male |
| Sarah Elizabeth Duncan | Chief Financial Officer & Company Secretary | 210.0K | female |
| Tom Scaccia | Senior Vice President of Americas & Research Business | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NIOX.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
